Table 3.

FDA response analysis in 155 mantle cell lymphoma patients

Response analyses (N = 155)n (%)95% CI
Overall response rate (CR + CRu + PR)48 (31)(24, 39)
    CR (CR + CRu)12 (8)(4, 13)
        CR10 (6)(3, 12)
        CRu2 (1)(0, 5)
    PR36 (23)(17, 31)
Duration of response, median (mo)
    CR + CRu + PR (n = 48)9.3(5.4, 13.8)
    CR + CRu (n = 12)15.4(13.4, 15.4)
    PR (n = 36)6.1(4.2, 9.3)